hat
NCT03392974. Faz 3 Etid Evalye Efficacité / Sekirite nan Valoctocogene Roxaparvovec yon AAV vektè-medyatè Gene Transfè nan hFVIII nan yon Dòz nan 4E13vg / kg nan Hemophilia A Pasyan ki gen rezidyèl FVIII Nivo ≤1IU / dL ki resevwa profiletik FVIII perfusion. https://clinicaltrials.gov/ct2/show/NCT03392974
eng
NCT03392974. Phase 3 Study to Evaluate Efficacy/Safety of Valoctocogene Roxaparvovec an AAV Vector-Mediated Gene Transfer of hFVIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions. https://clinicaltrials.gov/ct2/show/NCT03392974